Exhaled Breath Condensate confirming T790M mutation in a patient with EGFR-mutated Non-Small Cell Lung Cancer

Despite recent advances in the diagnosis and treatment of non-small cell lung cancer (NSCLC), most patients still present with advanced stage disease at the time of diagnosis. Recent studies suggest that IL-6 is involved in the development of lung cancer. The aim of the present study was to investigate whether the measurement of IL-6 levels in the breath condensate of NSCLC patients could be used to bring forward the moment of diagnosis and to monitor the progression of the disease. Twenty patients with histological evidence of NSCLC (14 men and 6 women, age 63±8 years) and 15 healthy controls (8 men and 7 women, age 45±6 years) were enrolled in the study. IL6 was measured in the exhaled breath condensate of patients and controls by means of a specific enzyme immunoassay kit. Higher concentrations of exhaled IL-6 were found in NSCLC patients (9.6±0.3 pg/mL) than in controls (3.5±0.2 pg/mL). A statistically significant difference was observed between patients with NSCLC at different stages: higher concentrations of IL-6 (10.9±0.5 pg/mL) were found in patients with metastatic disease than in those with stage III (9.7±0.4 pg/mL), stage II (8.9±0.3 pg/mL) and stage I disease (7.9±0.3 pg/mL). These findings suggest that the measurement of IL-6 in the breath condensate of patients with NSCLC could be proposed as a parameter to take into account in early diagnosis and disease monitoring.

Download Full-text

Analysis of p16 gene mutations and their expression using exhaled breath condensate in non-small-cell lung cancer

Oncology Letters ◽

10.3892/ol.2015.3426 ◽

2015 ◽

Vol 10 (3) ◽

pp. 1477-1480 ◽

Cited By ~ 5

Author(s):

JIN-LIANG CHEN ◽

JIAN-RONG CHEN ◽

FEN-FEN HUANG ◽

GUO-HUA TAO ◽

FENG ZHOU ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Exhaled Breath Condensate ◽

Gene Mutations ◽

Small Cell ◽

Exhaled Breath ◽

Small Cell Lung ◽

P16 Gene ◽

Breath Condensate

Download Full-text

Clinical Value of Serum and Exhaled Breath Condensate miR-186 and IL-1β Levels in Non-Small Cell Lung Cancer

Technology in Cancer Research & Treatment ◽

10.1177/1533033820947490 ◽

2020 ◽

Vol 19 ◽

pp. 153303382094749

Author(s):

Haiqin Xie ◽

Jinliang Chen ◽

Xuedong Lv ◽

Lu Zhang ◽

Jinnan Wu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Exhaled Breath Condensate ◽

Small Cell ◽

Expression Level ◽

Exhaled Breath ◽

Small Cell Lung ◽

Diagnostic Efficacy ◽

Breath Condensate

Objective: Our study aimed to investigate the expression level and clinical significance of serum and exhaled breath condensate miR-186 and IL-1β in non-small cell lung cancer patients. Methods: The serum and exhaled breath condensate specimens of 62 non-small cell lung cancer patients and 60 healthy controls were collected to detect miR-186 expression levels by real-time fluorescent quantitative PCR. Enzyme linked immunosorbent assay was applied to examine IL-1β concentration. Statistical analyses were used to evaluate the correlation between miR-186 and IL-1β in serum and clinicopathological features, traditional serum tumor markers, and inflammatory markers. The diagnostic efficacy of miR-186 and IL-1β for non-small cell lung cancer was evaluated by receiver operating characteristic curve analysis. The correlation between miR-186 and IL-1β was determined. Results: ① The relative expression level of miR-186 was greatly reduced in the serum and EBC of patients with non-small cell lung cancer, and the miR-186 expression level was reduced in different TNM stages of non-small cell lung cancer, from the early to later stages. ② The IL-1β concentration in serum and exhaled breath condensate of patients with non-small cell lung cancer was increased. ③ Serum miR-186 and IL-1β levels were closely related to lymph node metastasis, and the low expression of serum miR-186 and the high concentration of IL-1β were associated with higher serum carcinoembryonic antigen, C-reactive protein, and erythrocyte sedimentation rate levels. ④ ROC curve analysis showed that exhaled breath condensate miR-186 had higher area under the curve than serum miR-186, and the combined detection showed higher diagnostic efficacy than the separate detection. In addition, the combined detection of IL-1β and miR-186 has a larger AUC than the separate detection of both. ⑤ The correlation between serum miR-186 and IL-1β was negative. Conclusion: miR-186 and IL-1β are expected to be potential diagnostic biomarkers for non-small cell lung cancer.

Download Full-text

3p Microsatellite Alterations in Exhaled Breath Condensate from Patients with Non–Small Cell Lung Cancer

American Journal of Respiratory and Critical Care Medicine ◽

10.1164/rccm.200503-439oc ◽

2005 ◽

Vol 172 (6) ◽

pp. 738-744 ◽

Cited By ~ 57

Author(s):

Giovanna E. Carpagnano ◽

Maria Pia Foschino-Barbaro ◽

Giuseppina Mulé ◽

Onofrio Resta ◽

Stefania Tommasi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Exhaled Breath Condensate ◽

Small Cell ◽

Exhaled Breath ◽

Small Cell Lung ◽

Breath Condensate

Download Full-text

Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000353 ◽

2015 ◽

Vol 10 (1) ◽

pp. 93-101 ◽

Cited By ~ 24

Author(s):

Yosuke Togashi ◽

Hidetoshi Hayashi ◽

Masato Terashima ◽

Marco A de Velasco ◽

Kazuko Sakai ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Anticancer Effect ◽

Small Cell Lung ◽

T790m Mutation ◽

Egfr Mutated ◽

Egfr Tki

Download Full-text

Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2021/6968194 ◽

2021 ◽

Vol 2021 ◽

pp. 1-9

Author(s):

Milan Zhang ◽

Weifeng Ma ◽

Huiqin Liu ◽

Yushu Jiang ◽

Lingzhi Qin ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

T790m Mutation ◽

Mutation Status ◽

Mutational Status ◽

Egfr Mutated

Osimertinib has demonstrated promising efficacy against leptomeningeal metastasis (LM) associated with T790M-positive non-small-cell lung cancer (NSCLC). However, the effect of cerebrospinal fluid’s (CSF’s) epidermal growth factor receptor (EGFR) T790M mutation on osimertinib efficacy remains unclear.Seventy-eight patients were studied with EGFR-mutated NSCLC and LM. Case data were collected and EGFR mutation status of circulating cell-free DNA from paired CSF, and plasma of 23 patients with LM was detected using droplet digital PCR. The median overall survival (mOS) was 8.08 months (95% CI: 6.07–10.09) in the study. Forty-four osimertinib-treated patients had an improved mOS of 13.15 (95% CI: 5.74–20.57) and a median progression-free survival (PFS) of 9.50 months (95% CI: 6.77–12.23) when compared with patients treated with first- or second-generation EGFR-TKI (mOS = 3.00 months (95% CI: 1.32–4.68) and median PFS = 1.50 months (95% CI: 0.00–3.14)). In the osimertinib group, mOS values for CSF with and without T790M mutation were 22.15 months (95% CI: 9.44–34.87) and 13.39 months (95% CI: 7.01–19.76), respectively, with no statistical differences. Regardless of the CSF T790M mutation status, osimertinib demonstrated significant efficacy against LM associated with NSCLC.

Download Full-text